DAX25.140 +0,6%Est506.321 +0,4%MSCI World4.343 -0,1%Top 10 Crypto8,4500 +4,5%Nas26.457 -0,2%Bitcoin57.064 +3,3%Euro1,1436 -0,3%Öl77,92 -3,1%Gold4.206 +1,2%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
SpaceX A42D4F SAP 716460 Infineon 623100 Rheinmetall 703000 Deutsche Telekom 555750 NVIDIA 918422 Siemens Energy ENER6Y Volkswagen (VW) vz. 766403 Micron Technology 869020 Lufthansa 823212 Allianz 840400 Mercedes-Benz Group (ex Daimler) 710000 BMW 519000 Deutsche Bank 514000 Microsoft 870747
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
US-Iran-Gespräche: DAX wieder über 25.000 Punkten -- US-Börsen in Grün -- HOCHTIEF springt in den DAX -- OHB, Infineon, Intel, Micron, Siemens Energy, LG, SK hynix, Rheinmetall, Tesla im Fokus
Top News
Apogee-Aktie hebt ab: Milliarden-Übernahme durch AbbVie sorgt für Kurssprung Apogee-Aktie hebt ab: Milliarden-Übernahme durch AbbVie sorgt für Kurssprung
NASDAQ Composite Index-Wert Intel-Aktie: So viel Gewinn hätte eine Investition in Intel von vor 3 Jahren abgeworfen NASDAQ Composite Index-Wert Intel-Aktie: So viel Gewinn hätte eine Investition in Intel von vor 3 Jahren abgeworfen
Suche...
Jetzt kostenlos
bei finanzen.net anmelden
Watchlists & Musterdepots Tools & integriertes Trading Newsletter, Trading-Desk uvm.
Schon einen Account? Anmelden
Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Johnson Johnson Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
200,70 EUR +3,18 EUR +1,61 %
STU
229,11 USD +0,80 USD +0,35 %
BTT
finanzen.net zero
Johnson Johnson jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.480,04 Mrd. EUR

KGV18,82Div. Rendite2,48%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN853260

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS4781601046

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolJNJ

Johnson Johnson Aktien News

DatumMeistgelesen
PR NewswireJohnson & Johnson Teams Up with Naomi Watts to Reveal Why an Eye Exam is the Ultimate Self-Care Move for Women Over 40
EN, Johnson & JohnsonNew long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis
PR NewswireNew long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis
EN, Johnson & JohnsonJohnson & Johnson set to revolutionize the treatment of cancer with the acquisition of Halda Therapeutics
EN, Johnson & JohnsonDARZALEX FASPRO® is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma
PR NewswireDARZALEX FASPRO® is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma
EN, Johnson & JohnsonFDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder
PR NewswireFDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder
EN, Johnson & JohnsonJohnson & Johnson reinforces its leadership in hematology at ASH 2025 unveiling new paradigm-shifting research
EN, Johnson & JohnsonJohnson & Johnson One Year Data Demonstrate Durable Performance and Safety of the Shockwave Javelin Peripheral IVL Catheter in Late-Breaking Presentation at VIVA 2025
EN, Johnson & JohnsonJohnson & Johnson Confirms Durability of IVL in Complex, Below-the-Knee Anatomy in Late-Breaking Presentation at VIVA 2025
EN, Johnson & JohnsonJohnson & Johnson Showcases Latest Advancements in Pulsed Field Ablation with Multiple Clinical and Real-world Studies at APHRS and JPHRS
EN, Johnson & JohnsonJohnson & Johnson submits application to U.S. FDA for STELARA® (ustekinumab) in the treatment of pediatric ulcerative colitis
PR NewswireJohnson & Johnson announces first head-to-head study comparing IMAAVY™ with an alternative FcRn blocker in generalized myasthenia gravis (gMG) at AANEM Annual Meeting
EN, Johnson & JohnsonJohnson & Johnson announces first head-to-head study comparing IMAAVY™ with an alternative FcRn blocker in generalized myasthenia gravis (gMG) at AANEM Annual Meeting
EN, Johnson & JohnsonJohnson & Johnson to Advance Robotics Development with NVIDIA Isaac for Healthcare
EN, Johnson & JohnsonNew study reveals substantial unmet need in psoriasis, shows strong patient and provider preference for highly effective oral treatments with favorable safety profile
EN, Johnson & JohnsonJohnson & Johnson Advances Polyphonic™ AI Fund for Surgery for Data-Driven Healthcare
PR NewswireNew study reveals substantial unmet need in psoriasis, shows strong patient and provider preference for highly effective oral treatments with favorable safety profile
EN, Johnson & JohnsonTREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn’s disease at two years
EN, Johnson & JohnsonIcotrokinra maintains standout combination of therapeutic benefit and a favorable safety profile in once-daily pill through 28 weeks in ulcerative colitis
PR NewswireIcotrokinra maintains standout combination of therapeutic benefit and a favorable safety profile in once-daily pill through 28 weeks in ulcerative colitis
PR NewswireTREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn's disease at two years
PR NewswirePublished in The Lancet: Nipocalimab significantly decreased Sjögren's disease (SjD) activity and severity through substantial reduction in Sjögren's-related autoantibodies
EN, Johnson & JohnsonPublished in The Lancet: Nipocalimab significantly decreased Sjögren’s disease (SjD) activity and severity through substantial reduction in Sjögren’s-related autoantibodies
PR NewswireIcotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favorable safety profile in difficult-to-treat scalp and genital psoriasis
EN, Johnson & JohnsonIcotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favorable safety profile in difficult-to-treat scalp and genital psoriasis
EN, Johnson & JohnsonJohnson & Johnson MedTech Highlights Newest Impella Heart Pump and Long-Term Survival Data at TCT 2025
EN, Johnson & JohnsonJohnson & Johnson’s INLEXZO™ (gemcitabine intravesical system) plus cetrelimab delivers strong pre-surgical results in patients with muscle invasive bladder cancer scheduled for radical cystectomy
EN, Johnson & JohnsonSubcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer
PR NewswireSubcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer
PR NewswireTECVAYLI® plus DARZALEX FASPRO® combination regimen significantly improves progression-free survival and overall survival versus standard of care
EN, Johnson & JohnsonTECVAYLI® plus DARZALEX FASPRO® combination regimen significantly improves progression-free survival and overall survival versus standard of care
EN, Johnson & JohnsonJohnson & Johnson enters new era in solid tumors at ESMO 2025 with promising data across multiple cancer types
EN, Johnson & JohnsonJohnson & Johnson announces intent to separate its Orthopaedics business
EN, Johnson & JohnsonJohnson & Johnson reports Q3 2025 results; raises 2025 sales outlook
EN, Johnson & JohnsonJohnson & Johnson Launches INHANCE INTACT™: A Total Shoulder Replacement System Designed for Tissue-Sparing Surgery Providing Day-One Post-Op Mobility
EN, Johnson & JohnsonJohnson & Johnson Initiates CORE-VA Registry to Advance Ventricular Arrhythmia Ablation Care*
PR NewswireJohnson & Johnson to highlight breadth of its major depressive disorder portfolio at 2025 ECNP Congress
EN, Johnson & JohnsonJohnson & Johnson to highlight breadth of its major depressive disorder portfolio at 2025 ECNP Congress

Johnson Johnson News

Johnson Johnson News: auf dieser Seite finden Sie alle Johnson Johnson News und Nachrichten zur Johnson Johnson Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Johnson Johnson News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Johnson Johnson News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.